RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies
Infusion of CD19-Specific Chimeric Antigen Receptor T-cells Produced by Rapid Personalized Manufacture for Patients With Advanced Lymphoid Malignancies
Sponsor: Eden BioCell Ltd.
Terminated
CAR-T manufacturing technology can not meet the dose requirement for clinical patients.
Other B-cell Acute Lymphoblastic Leukemia trials with similar outcome
A PHASE1 clinical study on B-cell Acute Lymphoblastic Leukemia and Diffuse Large B Cell Lymphoma, this trial is terminated or withdrawn. The trial is conducted by Eden BioCell Ltd. and has accumulated 4 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jun 2022 — Jul 2024 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
May 2021 — Jun 2022 [monthly]
Recruiting PHASE1
First recorded
Mar 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eden BioCell Ltd.
- National Taiwan University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .